Skip to content

Biomarkers of Homeopathy in Fibromyalgia

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00065702
Enrollment
60
Registered
2003-08-01
Start date
2000-10-31
Completion date
2002-09-30
Last updated
2006-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia

Keywords

fibromyalgia, homeopathy, EEG, EKG, chronic pain

Brief summary

The purpose of this study is to evaluate the efficacy of individualized classical homeopathy in treatment of persons with fibromyalgia and to determine the usefulness of electroencephalographic and electrocardiographic measures to serve as markers of differences between active and placebo treatment.

Interventions

DRUGActive liquid remedy

Sponsors

National Center for Complementary and Integrative Health (NCCIH)
Lead SponsorNIH

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* ACR diagnosis of fibromyalgia; * Willing to take daily active or placebo liquid remedy under double blind conditions for 6 months, involving daily succussion and dilution of source liquid from a stock bottle; * Willingness/ability to comply with dietary and lifestyle restrictions, i.e., no coffee in any form, no comphor or menthol-containing products; no electric blankets, no strong aromatics, no routine vaccinations, no concomitant use of acupuncture, chiropractic, polarity therapy, psychic healing, or magnet therapy; * No dental drilling, MRI scans unless emergent; * Withhold food or drink 30 mins before/after therapy; * Stable conventional care for 2 months prior to entry; * Willing to undergo 3 diagnostic physical exams, and to permit videotaping of interview sessions; * Willing to fill out questionnaires

Exclusion criteria

* Steroid-dependent medical conditions; * Chronic benzodiazepine or anticonvulsant use; * Use of tricyclic antidepressants, antihypertensives, and other drugs that alter orthostasis; * Pregnancy; * History of seizure disorder or syncope; * Life-threatening medical conditions; * Current active asthma; * History of anaphylactic shock; * Insulin-dependent diabetes; * Active suicidal ideation or psychosis.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026